文献速递肝病消化道肿瘤与早癌

YAP/TAZ通过激活基质抑制药物渗透肝细胞癌

YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation.
PubMed 文献 · Hepatology · 2021-08-25

该研究利用流体动力转染法构建多种癌基因诱导的小鼠肝细胞癌模型,并建立含肝星状细胞、成纤维细胞和内皮细胞的多细胞肝癌类器官。结果显示,肝癌细胞中高YAP/TAZ活性导致肿瘤基质活化并损害维替泊芬向癌组织的渗透;抑制YAP/TAZ转录活性可显著增加药物向类器官的渗透。结论提示靶向活化的肿瘤基质可能改善高YAP/TAZ活性肝细胞癌的药物递送。

要点

  • 肝癌细胞高YAP/TAZ活性与基质活化相关,阻碍药物向肿瘤渗透。
  • 多细胞肝癌类器官可模拟YAP/TAZ介导的基质活化与药物渗透障碍。
  • 抑制YAP/TAZ转录活性可增加药物向肝癌类器官的渗透。

核心结论

  • 肝癌细胞中YAP/TAZ信号及其引发的基质活化会损害药物向肝细胞癌的递送。
  • 破坏或靶向活化的肿瘤基质可能改善高YAP/TAZ活性肝细胞癌的药物递送。

研究设计与样本

  • 研究采用流体动力转染法构建多种癌基因诱导的小鼠肝细胞癌模型,并在转染后5周给予维替泊芬治疗。
  • 建立含肝星状细胞、成纤维细胞和内皮细胞及肝癌细胞的多细胞肝癌类器官,用荧光显微镜评估维替泊芬分布。

主要发现

  • 流体动力转染法构建的小鼠肝细胞癌模型中,肝癌细胞高YAP/TAZ活性损害维替泊芬向癌组织的渗透。
  • 高YAP/TAZ活性的肝细胞癌中观察到肿瘤基质活化。
  • 多细胞肝癌类器官中激活YAP/TAZ信号可导致基质活化并损害维替泊芬向类器官的渗透。
  • 抑制肝癌细胞YAP/TAZ转录活性可显著增加药物向多细胞肝癌类器官的渗透。

临床怎么用

  • 对于高YAP/TAZ活性的肝细胞癌,可考虑联合靶向活化的肿瘤基质以改善药物递送。

局限性

  • 研究基于小鼠模型和多细胞类器官,尚未在患者中验证。
  • 药物渗透评估主要采用维替泊芬,其他药物的适用性未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: HCC is the most predominant type of liver cancer affecting 800,000 people globally each year. Various small-molecule compounds targeting diverse oncogenic signaling pathways have been tested for patients with HCC, and clinical outcomes were not satisfactory. In this study, we investigated molecular signaling that determines the efficiency of drug delivery into HCC. APPROACH AND RESULTS: Hydrodynamics-based transfection (HT) was performed to develop mouse models for HCC induced by various oncogenes. Mice bearing liver cancer were treated with verteporfin at 5 weeks after HT. Multicellular HCC organoid (MCHO) models were established that contained various types of stromal cells, such as hepatic stellate cells, fibroblasts, and endothelial cells together with HCC cells. Tumor organoids were treated with verteporfin, and distributions of the drug in the organoids were assessed using fluorescence microscopy. Murine HCC models developed by HT methods showed that a high Yes-associated protein/Transcriptional co-activator with PDZ-binding motif (YAP/TAZ) activity in HCC cells impaired verteporfin penetration into the cancer. Activation of tumor stroma was observed in HCC with a high YAP/TAZ activity. Consistent with the findings in the in vivo models of HCC, MCHOs with activated YAP/TAZ signaling showed stromal activation and impaired penetration of verteporfin into the tumor organoids. Inhibition of YAP/TAZ transcriptional activity in HCC cells significantly increased drug penetration into the MCHO. CONCLUSIONS: Drug delivery into liver cancer is impaired by YAP/TAZ signaling in tumor cells and subsequent activation of stroma by the signaling. Disrupting or targeting activated tumor stroma might improve drug delivery into HCC with an elevated YAP/TAZ activity.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Cho K, Ro SW, Lee HW, et al. YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation. Hepatology. 2021. PMID: 34101869. doi:10.1002/hep.32000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。